Global Pleural Effusions Treatment Market - 2022-2029

Global Pleural Effusions Treatment Market - 2022-2029

Market Overview

The global pleural effusions treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Pleural effusion treatment refers to treating an abnormal fluid collection between the thin layers of tissue (pleura) that line the lung and the chest cavity wall.

Market Dynamics

The factors influencing the global pleural effusions treatment market are the growing advancement in the therapeutic evaluation of pleural effusions and the increasing incidence of pleural effusions.

The growing advancement in the therapeutic evaluation of pleural effusions is expected to drive the market growth

An excessive accumulation of fluid in the pleural space is a pleural effusion. It can cause a diagnostic conundrum for the treating physician because it could be related to lung or pleural disorders or a systemic disorder. The most common symptoms are dyspnea that worsens with exertion, a dry cough, and pleuritic chest pain. It's crucial to figure out what's causing the pleural effusion so you can treat it properly. In nearly 20% of cases, however, the cause of the pleural effusion is unknown. For new or unexplained pleural effusions, thoracocentesis should be performed. A pleural fluid transudate can be distinguished from an exudate using laboratory testing. Pleurodesis is the preferred treatment for recurrent effusions. Pleurodesis requires the visceral and parietal pleurae to be in opposition. Endobronchial tumors, extensive intrapleural tumor masses, or multiple pleural loculations resulting in trapped lungs are unlikely to respond.

Moreover, when pleural effusions are present, and infection is present, a thoracotomy is performed through a 6- to 8-inch incision in the chest. A thoracotomy is performed to remove all fibrous tissue and aid in the pleural space infection evacuation. To keep the fluid draining, patients will need chest tubes 2 to 2 weeks after surgery.

The limitations associated with pleural effusions treatment are expected to hamper the market growth

Many complications can arise because of treatment, such as minor pain and discomfort are common side effects of more invasive treatments, but they usually go away with time. The severity of the condition, the cause, and the treatment used will influence the likelihood of more serious complications.

For instance, some serious complications include pulmonary edoema or fluid in the lungs that can occur because of thoracentesis fluid being drained too quickly. When there is pus in the pleural space trapped lung, it is called partial collapsed lung infection or bleeding empyema when a layer forms. The lungs are surrounded by a layer that prevents them from expanding.

COVID-19 Impact Analysis

Pleural effusion is a pathological accumulation of fluid in the pleural space that is very common. Pleural effusion can be caused by various conditions, such as viral pleuritis, congestive heart failure, or cancer. The one-year mortality rate for patients with a non-malignant pleural effusion range from 25 to 57 percent. Pleural effusion was found in 10.3 percent of COVID-19 patients in a recent study, with refractory patients having a higher rate of pleural effusion than general COVID-19 patients, indicating a more obvious inflammatory response in the lung. Pleural effusion can indicate the presence of serious symptoms in some diseases. People with COVID-19 who developed pleural effusion were more likely to have severe inflammation and complications, which could affect their recovery chances, according to some scientists 2021. Hence, with growing pleural effusion cases covid-19 is expected to positively impact the global pleural effusions treatment market.

Segment Analysis

Based on type, the Transudative Pleural Effusions segment is expected to dominate the market growth in the forecast period

Fluid leaking into the pleural space causes transudative pleural effusion. This is caused by increased blood vessel pressure or a low blood protein count. The most common cause is heart failure. The fluid in a transudative pleural effusion is similar to that found in one's pleural space. It is caused by liquid leaking through the normal pleura. Unless it is extremely large, this type rarely needs to be drained. Congestive heart failure is the leading cause of pleural effusions in developed countries, accounting for the vast majority of transudative pleural effusions.

When the systemic factors that influence the formation or absorption of pleural fluid are altered, a transudative pleural effusion develops. The primary pathologic process does not affect the pleural surfaces. By examining the pleural fluid characteristics, a diagnosis of transudative effusion can be made quickly. Pleural effusions occur in about 6% of patients with liver cirrhosis. These effusions are usually unilateral and right-sided, but they can also be bilateral (16%) or unilateral (16 percent). They can range in size from tiny to colossal. Because hypoalbuminemia is common in cirrhotic patients, it's tempting to blame these effusions on lower plasma oncotic pressure, which promotes pleural fluid formation. On the other hand, these effusions are almost always associated with ascites, which are the main source of transudative effusion.

Geographical Analysis

North America region is expected to hold the largest market share in the global pleural effusions treatment market

The rise in technological advancements, the availability of organized healthcare facilities, and the rising prevalence of respiratory diseases are expected to drive market growth. According to the American Cancer Society, lung cancer was the deadliest cancer in the United States in 2018. It is the second most common cancer in both men and women, and it is the most common cause of malignant pleural effusion (MPE), accounting for roughly 30% of all MPEs.

Shortness of breath is the most common symptom of pleural effusion, caused by fluid accumulating in the chest and compressing the lung. The prognosis for a malignant pleural effusion is poor, with patients living only four months on average after diagnosis. Moreover, pleural effusion is difficult to quantify because it is usually a symptom of a more serious illness. Despite this, the number of cases in the United States is estimated to be at least 1.5 million per year.

Competitive Landscape

The global pleural effusions treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are B. Braun Melsungen, Becton, Dickinson and Company, Bearpac Medical, Biometrix, Cook Medical, Grena, Redax, Rocket Medical, Smith Medical, Pfm Medical AG

B. Braun Melsungen

Overview: B. Braun is a German medical and pharmaceutical device company with offices and production facilities in over 60 countries and more than 63,000 workers worldwide. Melsungen, in central Germany, is the company's headquarters.

Product Portfolio: Celsite DRAINAPORT Access Port Systems are designed for pleural and peritoneal use. It eliminates the need for multiple, painful punctures to drain malignant ascites or malignant pleural effusion. The Celsite DRAINAPORT can also be used to administer chemotherapy and hydration intra-peritoneally.

On September 15th, 2020, The FDA granted Bearpac Medical 510(k) clearance for its Passio pump drainage system, which is used to remove fluid from the lungs. The system has been approved for the treatment of pleural effusions in both malignant and symptomatic patients.

Why Purchase the Report?

Visualize the composition of the global pleural effusions treatment composition market segmentation by type, treatment, and end user, highlighting the key commercial assets and players.

Identify commercial opportunities in global pleural effusions treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global pleural effusions treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global pleural effusions treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers